Case Study

Novartis Venture Fund: Valuation dilemmas

9 pages
May 2006
Reference: IMD-1-0242

The Novartis Venture Fund is considering investing into a start up,Genedata, and must take into account the valuation analysis by boththe start up as well as Venture Valuation — an independent boutiqueorganization that specializes in valuing high growth potential startups.NVF uses the Venture Valuation inputs to determine how best tostructure the next round of financing for Genedata and the caserequires the reader to discuss and analyze pricing, further financingrequirements, and exit strategy for the fund.

Valuation, Start-up, Venture Capital, Pharmaceuticals, Investment Strategy, Fund
July 1999
Field Research
© 2005
Available Languages
Related material
Teaching note
Case clearing houses
IMD case studies are distributed through case clearing houses. In order to browse the collection and purchase copies please visit the links below.

The Case Centre

Cranfield University

Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Email [email protected]

Harvard Business School Publishing

60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]

Asia Pacific Case Center

NUCB Business School

1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]


Research Information & Knowledge Hub for additional information on IMD publications

Discover our latest research
IMD's faculty and research teams publish articles, case studies, books and reports on a wide range of topics